Jun 25, 2010 (PRN): Genome Technologies, LLC., today announced it has developed a patented technology called Functional genomic fingerprinting (FGF) that can significantly improve the efficiency of next generation sequencing. FGF enables the selective enrichment of functional regions across genomes using multiplex PCR analysis of targeted regions such as the exome, promoterome, or exon splice enhancers.

In the June 16, 2010 publication of PLoS ONE, Senapathy et al have demonstrated the feasibility of FGF in enriching exons. Dr. Periannan Senapathy lead author and founder CEO of Genome Technologies, LLC says “FGF has enormous advantages over currently employed sequence capture technologies such as array capture because it is a targeted, multiplexed PCR method that can ensure a very high level of specificity and efficiency of sequence enrichment.” In addition, he adds that “The high probability that genetic lesions bearing causal mutations of diseases and adverse drug effects are contained within these targeted regions gives the FGF technology momentous practical utility in drug discovery, diagnostics and agriculture.”

FGF is a viable and cost-effective alternative to array and solution based hybridization enrichment technologies. In addition to its capability to compare fingerprints of functional regions from different genomes for studies including genotypic differences among species, FGF can be an effective front-end target enrichment strategy for NGS platforms, with a variety of human, veterinary and plant biotechnology applications.

About Genome Technologies, LLC.

Based in Madison, Wisconsin, Genome Technologies LLC. is a genomics technology company that develops, manufactures, and markets fully-integrated platform analysis techniques for genotyping, target enrichment and next generation sequencing and analysis. The company's systems enable powerful and sophisticated genome wide analysis for agriculture, veterinary and human biotechnology applications. Through its strong genomics capabilities, Genome Technologies is focusing on next generation sequencing applications including target enrichment. The company's proprietary capabilities in fingerprinting functional regions will enable new signatures for pathogen, forensic and trait identification in biomedical, veterinary and agricultural fields. [Wired by: PressReleaseNetwork.com]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.